Previous close | 8.57 |
Open | 8.68 |
Bid | 0.00 x 800 |
Ask | 0.00 x 800 |
Day's range | 8.06 - 8.78 |
52-week range | 8.06 - 35.75 |
Volume | |
Avg. volume | 167,337 |
Market cap | 354.006M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
CAMBRIDGE, Mass. & MONTREAL, May 09, 2022--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the virtual 2022 Guggenheim Synthetic Lethality Day on Monday, May 16, 2022 at 9:00 a.m. Eastern Time.
CAMBRIDGE, Mass. & MONTREAL, May 05, 2022--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022.
CAMBRIDGE, Mass. & MONTREAL, April 20, 2022--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that preclinical data demonstrating inhibition of CCNE1-amplified tumor growth in vivo by selective inhibition of PKMYT1 using RP-6306, a first-in-class small molecule candidate targeting PKMYT1, were published in Nature. SNIPRx®, Repare’s proprietary, genome-wide, CRISPR-based screening approach, was used to uncove